作者
Marc A Pfeffer, Brian Claggett, Eldrin F Lewis, Christopher B Granger, Lars Køber, Aldo P Maggioni, Douglas L Mann, John JV McMurray, Jean-Lucien Rouleau, Scott D Solomon, Philippe Gabriel Steg, Otavio Berwanger, Maja Cikes, Carmine G De Pasquale, Alberto Fernandez, Gerasimos Filippatos, Karola Jering, Ulf Landmesser, Venugopal Menon, Béla Merkely, Mark C Petrie, Ivo Petrov, Morten Schou, Michele Senni, David Sim, Peter Van Der Meer, Martin Lefkowitz, Yinong Zhou, Yi Wang, Eugene Braunwald
发表日期
2022/1/4
期刊
Circulation
卷号
145
期号
1
页码范围
87-89
出版商
Lippincott Williams & Wilkins
简介
Methods
The design, baseline characteristics, and primary results of this institutional review board–approved trial are published. 1, 2 In brief, PARADISE-MI was a double-blind, active-controlled randomized, clinical trial that compared sacubitril/valsartan with ramipril in 5661 patients with written informed consent, an acute myocardial infarction (within 0.5–7 days of presentation) with either left ventricular ejection fraction≤ 40% or transient pulmonary congestion. Previous heart failure or clinical instability (requiring intravenous diuretics, inotropes, or blood pressure support within the 24 hours before randomization) were major exclusions, and all patients provided written informed consent.
学术搜索中的文章
MA Pfeffer, B Claggett, EF Lewis, CB Granger, L Køber… - Circulation, 2022